U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07665073) titled 'Risperidone vs Cariprazine in Acute Mania' on June 18.
Brief Summary: Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks. Primary outcome is change in YMRS total score from baseline to week 6.
Study Start Date: June, 2027
Study Type: INTERVENTIONAL
Condition:
Bipolar 1 Disorder
Intervention:
DRUG: Risperidone
Oral Risperidone tablets, 2-6 mg/day administered once daily for 6 weeks. Dose titrated based on clinical response and tolerability. Approved antipsychotic for acute mania...